MannKind Corporation
Use of Ultrarapid Acting Insulin

Last updated:

Abstract:

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Status:
Application
Type:

Utility

Filling date:

14 Aug 2020

Issue date:

24 Dec 2020